Patient Dies after Treatment with Intellia CRISPR Therapy in Phase III Trial.

The current development of genetic engineering has been able to intervene in the treatment of many disease areas, especially immune diseases have shown the need for gene editing. The importance of target correspondence is evident at all stages of research. Neurodegenerative diseases have always been a struggling area of medicine, but the current mainstream gene-based immunotherapy has given people the possibility of curing or improving neurological diseases. In the investigation and deepening understanding, at least one immunotherapy has practical application, but the other has not shown the achievements in the direction of neurobiology. Even though immunotherapy is indelible, especially in cancer tumors, the more possibilities of these therapies and the progress of current development are worthy of attention and repeated research. CRISPR therapy is not only able to effectively insert and modify or knock out targeted gene segments in treatment; it is also used to discover the pathogenesis of certain diseases, the pathogenesis suspected by scientists, such as whether the expression level of a certain protein That can be controlled by increasing or decreasing gene expression, both achievable through the implementation of CRISPR therapies. In this review, we summarizes CAR-T and CRISPR therapies in Alzheimer's Disease.

A new study uses CRISPR-based transcriptional modulation as an in vivo therapeutic in various mouse models of human diseases.

Gene therapy: CRISPR therapies - making the grade not the cut.

The world's first CRISPR therapy is approved: who will receive it?

CRISPR-Cas9 is a novel gene-editing tool that promised to revolutionize our ability to treat genetic conditions when first introduced. Today, it continues to fuel many areas of health research, ranging from cancers to sickle cell disease to Huntington’s disease.1–3 Vision science researchers immediately saw the potential of CRISPR, with some of the earliest experiments exploring CRISPR as a treatment option for inherited ocular disorders.4 Only a few years later, in March 2020, vision research was again at the forefront of this field.5 A CRISPR therapy was injected into the human body for the first time in an attempt to correct a vision threatening mutation.5 Inherited retinal diseases have traditionally presented therapeutic challenges, but CRISPR is now providing hope for a cure.

Safety concerns surrounding AAV and CRISPR therapies in neuromuscular treatment

Casgevy, the world's first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.

Chromatin Interactions and Regulatory Elements in Cancer: From Bench to Bedside

BackgroundThe development of sequence-specific precision treatments like CRISPR gene editing therapies for Duchenne muscular dystrophy (DMD) requires sequence humanized animal models to enable the direct clinical translation of tested strategies. The current available integrated transgenic mouse model containing the full-length human DMD gene, Tg(DMD)72Thoen/J (hDMDTg), has been found to have two copies of the transgene per locus in a tail-to-tail orientation, which does not accurately simulate the true (single) copy number of the DMD gene. This duplication also complicates analysis when testing CRISPR therapy editing outcomes, as large genetic alterations and rearrangements can occur between the cut sites on the two transgenes.ResultsTo address this, we performed long read nanopore sequencing on hDMDTg mice to better understand the structure of the duplicated transgenes. Following that, we performed a megabase-scale deletion of one of the transgenes by CRISPR zygotic microinjection to generate a single-copy, full-length, humanized DMD transgenic mouse model (hDMDTgSc). Functional, molecular, and histological characterisation shows that the single remaining human transgene retains its function and rescues the dystrophic phenotype caused by endogenous murine Dmd knockout.ConclusionsOur unique hDMDTgSc mouse model simulates the true copy number of the DMD gene, and can potentially be used for the further generation of DMD disease models that would be better suited for the pre-clinical assessment and development of sequence specific CRISPR therapies.

Gene and cell therapies have shown tremendous advancement in the last 5 years. Prominent examples include the successful use of CRISPR-edited stem cells for treating blood disorders like sickle cell anemia and beta-thalassemia, and ongoing clinical trials for treating blindness. This mini-review assesses the status of CRISPR-based therapies, both in vivo and ex vivo, and the challenges associated with clinical translation. In vivo CRISPR therapies have been used to treat eye and liver diseases due to the practicality of delivering editing components to the target tissue. In contrast, even though ex vivo CRISPR therapy involves cell isolation, expansion, and infusion, its advantages include characterizing the gene edits before infusion and restricting off-target effects in other tissues. Further, the safety, affordability, and feasibility of CRISPR therapies, especially for treating large number of patients, are discussed.

BackgroundCurrently, there are no curative drugs for hepatitis B virus (HBV). Complete elimination of HBV covalently closed circular DNA (cccDNA) is key to the complete cure of hepatitis B virus infection. The CRISPR/Cas9 system can directly destroy HBV cccDNA. However, a CRISPR/Cas9 delivery system with low immunogenicity and high efficiency has not yet been established. Moreover, effective implementation of precise remote spatiotemporal operations in CRISPR/Cas9 is a major limitation.ResultsIn this work, we designed NIR-responsive biomimetic nanoparticles (UCNPs-Cas9@CM), which could effectively deliver Cas9 RNP to achieve effective genome editing for HBV therapy. HBsAg, HBeAg, HBV pgRNA and HBV DNA along with cccDNA in HBV-infected cells were found to be inhibited. These findings were confirmed in HBV-Tg mice, which did not exhibit significant cytotoxicity and minimal off-target DNA damage.ConclusionsThe UCNPs-based biomimetic nanoplatforms achieved the inhibition of HBV replication via CRISPR therapy and it is a potential system for efficient treatment of human HBV diseases.Graphical

CRISPR technology holds promise as a potential treatment for inherited neuropathies, such as Charcot-Marie-Tooth disease (CMT), through gene correction, silencing, regulation, and cell therapy. Gene correction involves editing faulty DNA sequences, whereas gene silencing suppresses the expression of disease-causing genes. Gene regulation modulates gene expression levels related to neuropathy pathology. Cell therapy involves transplanting CRISPR-engineered cells to replace damaged cells with healthy ones. However, challenges hinder the widespread application of CRISPR technology in treating inherited neuropathies. These include the need for efficient and safe delivery of CRISPR components, minimizing off-target effects, and addressing ethical and regulatory considerations. Research efforts are underway to overcome these challenges and advance CRISPR technology for clinical applications in neuropathy treatment. Despite these obstacles, CRISPR therapies have the potential to revolutionize the management of debilitating inherited neuropathies.

Glioblastoma is a notorious malignant tumor and traits in cancer provide strong drug resistance. Current Traditional clinical treatments include chemotherapy and surgery, had been proved that showed insufficient effect towards glioblastoma, leading to the requirement of new therapy ------ CRISPR mediated technology therapy application. CRISPR is prior options for gene therapy drug design and using gene-editing principle from the molecular level. Scientists research evaluated the CRIPSR gene therapy had ability in editing related functions of glioblastomas and inducing an immune response by blocking the metabolic activity of cancer cells to achieve anti-cancer effects. We discussed the recent identified potential CRISPR gene therapy targeting sites in glioblastoma gene therapy, including clinical traits and in vivo experiments verified the value in future clinical treatment applications. We also discussed the relationship between the target sites of the glioblastoma genome and the traits they related with. Targeting the angiogenesis regulator factors leads to suppression of glioblastoma proliferation and inhibit the tumor growth. Mediated the tumor micro environment by enhancing antigen present process and reduce glioblastoma interaction with immune cells, could up regulated the anti-tumor immune response. The is also a possibility of combining immune therapy and CRIPSR gene editing therapy together by Car-T therapy. We also discuss the potential delivery method for CRISPR gene-editing therapy, compare the AAV virus method and nanocapsule for assist the edited gene reach the target sties and avoid off-target rate. The CRISPR therapy could be the mainstay in glioblastoma treatment by directly target the glioblastoma metabolism to inhibit tumor proliferation, and could increase survival rate in child glioblastoma treatment as the heterogeneity of glioblastoma is high.

Watershed year of cell and gene therapy (CGT): A review of 2024 CGT approvals.

Tools based on RNA interference (RNAi) and the recently developed clustered regularly short palindromic repeats (CRISPR) system enable the selective modification of gene expression, which also makes them attractive therapeutic reagents for combating HIV infection and other infectious diseases. Several parallels can be drawn between the RNAi and CRISPR-Cas9 platforms. An ideal RNAi or CRISPR-Cas9 therapeutic strategy for treating infectious or genetic diseases should exhibit potency, high specificity and safety. However, therapeutic applications of RNAi and CRISPR-Cas9 have been challenged by several major limitations, some of which can be overcome by optimal design of the therapy or the design of improved reagents. In this review, we will discuss some advantages and limitations of anti-HIV strategies based on RNAi and CRISPR-Cas9 with a focus on the efficiency, specificity, off-target effects and delivery methods.